# A Safety and Efficacy Trial of TTHX1114 in People With CED

> **NCT04812067** · PHASE2 · COMPLETED · sponsor: **Trefoil Therapeutics, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Corneal Endothelial Dystrophy

## Interventions

- **DRUG:** TTHX1114

## Key facts

- **NCT ID:** NCT04812067
- **Lead sponsor:** Trefoil Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-10-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812067, "A Safety and Efficacy Trial of TTHX1114 in People With CED". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04812067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*